

NASHP's Prescription Drug Cost Workgroup

A Project of the National Academy for State Health Policy

Supported by The Laura and John Arnold Foundation and Kaiser Permanente

State	Bill	Status	Category	Summary
AL	HB 177	Referred to House of Representatives Ways and Means Committee	Volume Purchasing	Creates the Alabama Prescription Cost Initiative Board. The board may enter into agreements with or affiliate with a prescription drug-buying group for the centralized purchase and distribution of prescription drugs to retail pharmacies. Reimportation of prescription drugs is expressly prohibited.
CA	AB 265	Pending	Other	Would prohibit the use of coupons for pharmaceutical drugs when other FDA-approved drugs are available and less expensive.
CA	S 17	Pending	Transparency	Would require manufacturers to provide public and private purchasers advance notice of price increases for the cost of prescription drugs currently on the market, and to provide information regarding justification for such increases, as well as justification of launch prices for new drugs.
CT	SB 737	Referred to Committee on General Law	Transparency	That the general statutes be amended to require every manufacturer of a prescription drug made available in the state to file a report regarding each such drug that contains the total cost for the production of the drug, including, but not limited to, (1) the total research and development costs paid by the manufacturer and by any predecessor of such manufacturer, (2) the total costs of clinical trials and other regulatory costs paid by the manufacturer and by any predecessor of such manufacturer, (3) the total costs for materials, manufacturing and administration of the drug, (4) any other costs associated with the acquisition of the drug, and (5) the total marketing and advertising costs for the promotion of the drug directly to potential prescribers and consumers.
CT	SB 445	Public Hearing	Transparency	Requires general statutes to be amended to require pharmaceutical price transparency and disclosure
CT	SB 925	Public Hearing	Transparency; Pharmacy Benefit Managers	Manufacturers shall send written notice to the commissioner if the manufacturer plans to: (1) Sell or distribute in this state (A) any brand name prescription drug that has an initial annual aggregate wholesale acquisition cost that is equal to or greater than thirty thousand dollars, or (B) any generic drug that has an initial annual aggregate wholesale acquisition cost that is equal to or greater than three thousand dollars; or (2) increase the annual aggregate wholesale acquisition cost of (A) any brand name prescription drug sold or distributed in this state by more than ten per cent or ten thousand dollars, whichever is lower, or (B) any generic drug sold or distributed in this state by more than twenty-five per cent or three hundred dollars, whichever is lower. Manufacturers must report the value of all price concessions provided to pharmacy benefit managers.
FL	HB 589	Introduced	Transparency; Study	Requires Agency for Health Care Administration to collect data on the retail prices charged by pharmacies for the 300 most frequently prescribed medicines; requires the agency to update the website monthly.
FL	SB 888	Introduced	Transparency; Study	Companion bill to HB 589
IL	SB 73	Pending	Transparency	Requires manufacturers of prescription drugs to notify State purchasers, health insurers, health care service plan providers, and pharmacy benefit managers of specified increases in drug prices at least 30 days before such increase and the cost of specified new prescription drugs 3 days before the commercial availability of a new drug approved by the U.S. Food and Drug Administration or within 3 days after approval by the U.S. Food and Drug Administration if the new drug will be made commercially available within 3 days of such approval. Provides that within 30 days after such notifications, prescription drug manufacturers shall report specified information to the Department of Public Health and requires the Department to publish such information on its website.
IL	HB 239	Pending	Transparency	Amends the Illinois Food, Drug and Cosmetic Act. Requires manufacturers of brand name or generic prescription drugs to notify State purchasers, health insurers, health care service plan providers, pharmacy benefit managers, and the General Assembly of specified increases in drug prices at least 60 days before such increase and the cost of specified new prescription drugs within 3 days after approval by the U.S. Food and Drug Administration. Provides that within 30 days after such notifications, prescription drug manufacturers shall report specified information to State purchasers, health insurers, health care service plan providers, pharmacy benefit managers, and the General Assembly. Provides that failure to report such information shall result in a specified civil penalty.
IN	HB 1150	Pending	Transparency	Requires the office of the secretary of family and social services to identify any prescription drug under the Medicaid program for which the annual wholesale cost or the per course cost of treatment of the drug is at least \$10,000, and directs the office to notify the manufacturer that the manufacturer is required to prepare a report on the drug to the drug utilization review board.
IN	SB 69	Committee on Health and Provider Services	Transparency; Study	Study of drug pricing and access. Urges the legislative council to assign to an interim study committee a study of prescription drug pricing and access to specialty prescription drugs. Requires submission of a report and recommendations to the legislative council.
KS	HB 2300	House Committee on Health and Human Services	Transparency; Pharmacy Benefit Managers	Requires pharmacy benefit managers (PBMs) contracting with the state health care benefits program to disclose any payment or benefit received for the dispensation of a prescription drug. The PBM will also disclose all financial and utilization information requested by the program. Any payment or benefit received by the PBM for the dispensation of a prescription drug will be passed along in full to the state.
MA	SD 1896	Pending	Study	Establishes a special commission to study the delivery of prescription drug benefits in the Commonwealth. The Commission shall study and analyze bulk purchasing, discount cards, private section insurance drug programs, pharmaceutical benefit managers, and other issues which may improve prescription drug benefits for the citizens of the Commonwealth.